Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.45 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.44 |
| ▸ | CBLB | Q13191 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595870 | 0.83 | KDR (0.54) | ALDH1A1DDR1GAATLR7ALKBH2 | |
| SCHEMBL18422426 | 0.83 | KDR (0.54) | ALDH1A1DDR1GAATLR7ALKBH2 | |
| SCHEMBL25199807 | 0.81 | DDR1 (0.51) | DDR1LOXL2TLR7ALKBH2ALKBH5 | |
| SCHEMBL2678073 | 0.81 | KMT2A (0.56) | ALDH1A1DDR1NOS3NOS2GAA | |
| SCHEMBL29838843 | 0.80 | NOS3 (0.52) | ALDH1A1DDR1NOS3NOS2GAA | |
| SCHEMBL20956597 | 0.80 | ALDH1A1 (0.45) | ALDH1A1DDR1NOS3NOS2LOXL2 | |
| Hydrochloric Acid SCHEMBL29537174 | 0.79 | KMT2A (0.54) | ALDH1A1DDR1NOS3NOS2GAA | |
| SCHEMBL25797141 | 0.79 | DDR1 (0.49) | ALDH1A1DDR1LOXL2GAATLR7 | |
| SCHEMBL29537506 | 0.79 | KDM4E (0.55) | ALDH1A1NOS3NOS2TLR7KDM4E | |
| SCHEMBL222146 | 0.79 | KDM4E (0.55) | ALDH1A1NOS3NOS2TLR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| EP-3309161-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-18 | — | — | EP | disclosed |
| EP-3309161-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-18 | — | — | EP | disclosed |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| US-10053462-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| EP-3309161-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309161-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-20170088550-A1 | P2X7 MODULATORS | Jansssen Pharmaceutica NV (BE) | 2017-03-30 | — | — | US | disclosed |
| US-9540388-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-10 | — | — | US | disclosed |
| US-9540388-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-10 | — | — | US | disclosed |
| US-20160039836-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970287-A1 | P2X7 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970304-A1 | P2X7 MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152537-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152621-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152621-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053462-B2 | P2X7 modulators | P2RX1, P2RX5, P2RX7 | ALDH1A1 997/4885NPSR1 210/4885DDR1 1809/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | ALDH1A1 1260/4885NPSR1 2949/4885DDR1 4560/4885 |
| US-20160016962-A1 | P2X7 MODULATORS | P2RX5, P2RX1, P2RX7 | ALDH1A1 2378/4885NPSR1 55/4885DDR1 2170/4885 |
| US-20160039836-A1 | P2X7 MODULATORS | P2RX1, P2RX7, P2RX5 | ALDH1A1 1077/4885NPSR1 220/4885DDR1 1686/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | ALDH1A1 658/4885NPSR1 1057/4885DDR1 4693/4885 |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | HTR5A, P2RX5, P2RX3 | ALDH1A1 2966/4885NPSR1 56/4885DDR1 2099/4885 |
| US-20170088550-A1 | P2X7 MODULATORS | P2RX1, P2RX5, P2RX7 | ALDH1A1 997/4885NPSR1 210/4885DDR1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.